L
Lars Henrik Jensen
Researcher at University of Southern Denmark
Publications - 121
Citations - 3326
Lars Henrik Jensen is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 17, co-authored 99 publications receiving 1751 citations. Previous affiliations of Lars Henrik Jensen include Odense University Hospital.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz,Keynote Investigators +21 more
TL;DR: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events.
Journal ArticleDOI
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study
Ane L Appelt,John Pløen,Henrik Harling,Frank Jensen,Lars Henrik Jensen,Jens Christian Riis Jørgensen,Jan Lindebjerg,Søren Rafael Rafaelsen,Anders Jakobsen +8 more
TL;DR: High-dose chemoradiotherapy and watchful waiting might be a safe alternative to abdominoperineal resection for patients with distal rectal cancer.
Journal ArticleDOI
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Alexander Stein,Dirk Arnold,John Bridgewater,David Goldstein,Lars Henrik Jensen,Heinz-Josef Klümpen,Ansgar W. Lohse,Björn Nashan,John N. Primrose,Silke Schrum,Jenny Shannon,Eik Vettorazzi,Henning Wege +12 more
TL;DR: The primary endpoint is DFS and secondary endpoints include OS, safety and tolerability of chemotherapy, quality of life, and patterns of disease recurrence.
Journal ArticleDOI
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz +19 more
TL;DR: LBA4 is a phase 3, randomized open-label study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard of care chemotherapy ± bevacIZumab o...
Journal ArticleDOI
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
TL;DR: Combination chemotherapy with panitumumab in patients with KRAS wild-type tumors met the efficacy criteria for future testing in a randomized trial, suggesting marker-driven patient selection is feasible in the systemic treatment of biliary tract cancer.